Global Stem Cell Manufacturing Market

Stem Cell Manufacturing Market Size, Share, Growth Analysis, By Product(Cell lines, instruments), By Distribution Channel(Direct sales and third-party distributors) - Industry Forecast 2024-2031


Report ID: SQMIG35B2172 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 61 | Figures: 75

Stem Cell Manufacturing Market News

  • In March 2023, The Medicines and Healthcare products Regulatory Agency (MHRA) announced that its UK Stem Cell Bank was testing automated robotic technology for growing stem cells.
  • In April 2023, Thermo Fisher Scientific Inc. launched a new cell culture media product for the manufacturing of stem cells.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Stem Cell Manufacturing Market size was valued at USD 11.5 Billion in 2021 and is poised to grow from USD 12.58 Billion in 2022 to USD 25.81 Billion by 2030, at a CAGR of 9.4% during the forecast period (2023-2030).

The stem cell manufacturing market features a competitive landscape with several players striving to establish their presence and gain a competitive edge. The market is characterised by the presence of multinational pharmaceutical companies, biotechnology firms, and research institutions. These players are engaged in continuous research and development activities to enhance their stem cell manufacturing capabilities and expand their product portfolios. The competitive landscape is influenced by factors such as technological advancements, product innovation, strategic collaborations, and regulatory compliance. Key players in the market focus on developing advanced manufacturing technologies, optimising cell culture techniques, and improving the scalability and reproducibility of stem cell production. These efforts aim to meet the increasing demand for stem cell-based therapies and capitalise on the market's potential. Moreover, strategic collaborations and partnerships play a crucial role in the competitive landscape of the stem cell manufacturing market. Companies form alliances with research institutions, academic centers, and other industry players to leverage their expertise, access to stem cell lines, and advanced technologies. These collaborations help in accelerating the development and commercialization of novel stem cell therapies and expanding market reach. In addition, regulatory compliance is a critical aspect of the competitive landscape. Stem cell manufacturing is subject to strict regulations and guidelines, and companies that demonstrate compliance with these regulations gain a competitive advantage. Adherence to quality control standards, documentation requirements, and ethical considerations is crucial for market players to ensure the safety and efficacy of their stem cell-based products. 'Thermo Fisher Scientific Inc. - US', 'Lonza Group Ltd. - Switzerland', 'Merck KGaA - Germany', 'FUJIFILM Cellular Dynamics Inc. - US', 'STEMCELL Technologies Inc. - Canada', 'Takara Bio Inc. - Japan', 'GE Healthcare - US', 'Miltenyi Biotec GmbH - Germany', 'PromoCell GmbH - Germany', 'CellGenix GmbH - Germany', 'REPROCELL Inc. - Japan', 'Cellular Dynamics International, a Fujifilm Company - US', 'STEMCELL Clinic - Canada', 'Osiris Therapeutics, Inc. - US', 'Pluristem Therapeutics Inc. - Israel', 'TiGenix NV - Belgium', 'Mesoblast Limited - Australia', 'Cellular Biomedicine Group, Inc. - US', 'Gamida Cell Ltd. - Israel', 'Vericel Corporation - US'

The rising incidence of chronic diseases, such as cardiovascular disorders, neurological conditions, and cancer, is a key driver for the stem cell manufacturing market. Stem cells offer potential therapeutic solutions and regenerative treatments for these diseases, driving the demand for stem cell manufacturing.

Focus on Ethical and Sustainable Sourcing of Stem Cells: There is a growing emphasis on ethical and sustainable sourcing of stem cells. The use of alternative sources, such as induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), is gaining traction. Companies are investing in research and development to develop efficient and ethical methods for deriving and culturing stem cells, reducing the reliance on controversial sources.

The dominant region in the stem cell manufacturing market is North America. North America holds a significant share of the market due to its advanced healthcare infrastructure, robust research and development activities, and strong presence of major pharmaceutical and biotechnology companies. The region has a well-established regulatory framework that supports stem cell research and development, making it an attractive market for stem cell manufacturing. Additionally, the presence of renowned research institutions and academic centers further drives the growth of the stem cell manufacturing market in North America.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Stem Cell Manufacturing Market

Product ID: SQMIG35B2172

$5,300
BUY NOW GET FREE SAMPLE